Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), and—as adjunctive therapies—atypical antipsychotics. Although this drug market is ingrained with generic therapies, MDD patients’ heterogeneous response to current drugs and the need for additional efficacious therapies give branded agents (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck], Spravato [Janssen]) the opportunity to be incorporated into the treatment algorithm. Given MDD’s highly competitive landscape encompassing both long-established and newer-to-market drugs, it is valuable for drug marketers and developers to understand physicians’ actual prescribing behavior in MDD. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for MDD.
Markets covered: United States.
Key companies: Lundbeck, Otsuka, Takeda, Janssen, Sunovion, AbbVie.
Key drugs: Trintellix, Rexulti, Latuda, Vraylar, Spravato, citalopram, escitalopram, fluoxetine, sertraline, duloxetine, venlafaxine, aripiprazole, quetiapine, bupropion hydrochloride SR/XL, mirtazapine.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.